Literature DB >> 10160087

Economic evaluation of vaccination against influenza in New Zealand.

W G Scott1, H M Scott.   

Abstract

The objective of this study was to evaluate the costs and benefits of influenza vaccination for the population aged 65 years and over, from the perspectives of individuals and health insurers, government and society. The annual incremental direct medical costs and benefits of influenza vaccination (compared with the nonvaccination, or 'do nothing', option) were evaluated using New Zealand healthcare resource usage and unit cost data [in 1992 New Zealand dollars ($NZ); $NZ1 = $US0.5458, June 1992] applied to cohort studies reported in the literature. The costs and benefits to society as a result of vaccination of people aged 65 years and older (20% of people in this age group are currently vaccinated) were estimated to be: (i) additional direct medical costs of vaccination of $NZ1.42 million [$NZ17.78 per vaccination]; (ii) direct medical costs avoided of $NZ5.35 million ($NZ67.18 per vaccination); and (iii) net benefits of $NZ3.93 million ($NZ49.40 per vaccination). The direct medical costs avoided per dollar cost of vaccination were $NZ1.04 for individuals, $NZ4.69 for government and $NZ3.78 for society as a whole. If the vaccination uptake for this group is increased in 20% increments, the net benefit to society increases by a further $NZ3.93 million per year at each step. If the economic evaluation is extended to include vaccination of at-risk individuals under 65 years of age, net benefits to society increase by 15%. Influenza vaccination for people aged 65 years and over is cost effective from the perspective of society, government and the individual. If the vaccination rate for at-risk individuals in New Zealand could be increased to 60%, the net benefits reported in this study would increase by 200%. However, the costs of promotion and education to achieve this vaccination rate would need to be deducted from the net benefits. Strategies to increase the vaccination rate include altering the cost of vaccinations to the individual, intensifying education and promotion programmes, and changing the mode of delivery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10160087     DOI: 10.2165/00019053-199609010-00006

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  9 in total

1.  Influenza vaccination and the elderly.

Authors:  K G Nicholson
Journal:  BMJ       Date:  1990-09-29

2.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

3.  Influenza mortality and excess deaths in the elderly, 1967-82.

Authors:  M J Sprenger; M A Van Naelten; P G Mulder; N Masurel
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

Review 4.  Influenza: diagnosis, management, and prophylaxis.

Authors:  M Wiselka
Journal:  BMJ       Date:  1994-05-21

5.  Community acquired pneumonia: aetiology and prognostic index evaluation.

Authors:  N C Karalus; R T Cursons; R A Leng; C B Mahood; R P Rothwell; B Hancock; S Cepulis; M Wawatai; L Coleman
Journal:  Thorax       Date:  1991-06       Impact factor: 9.139

6.  Clinical effectiveness of influenza vaccination in Manitoba.

Authors:  D S Fedson; A Wajda; J P Nicol; G W Hammond; D L Kaiser; L L Roos
Journal:  JAMA       Date:  1993-10-27       Impact factor: 56.272

7.  The effectiveness of vaccination against influenza in healthy, working adults.

Authors:  K L Nichol; A Lind; K L Margolis; M Murdoch; R McFadden; M Hauge; S Magnan; M Drake
Journal:  N Engl J Med       Date:  1995-10-05       Impact factor: 91.245

8.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.

Authors:  K L Nichol; K L Margolis; J Wuorenma; T Von Sternberg
Journal:  N Engl J Med       Date:  1994-09-22       Impact factor: 91.245

9.  Influenza vaccination.

Authors:  M A Riddiough; J E Sisk; J C Bell
Journal:  JAMA       Date:  1983-06-17       Impact factor: 56.272

  9 in total
  8 in total

1.  Influenza vaccination in 29 countries. An update to 1997.

Authors:  F Ambrosch; D S Fedson
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 2.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

3.  Exercise prescription in primary care.

Authors:  F Smith; S Iliffe
Journal:  Br J Gen Pract       Date:  1997-05       Impact factor: 5.386

4.  Influenza vaccine and older people: an evidence-based policy?

Authors:  M D Bradley; T A Sheldon; I S Watt
Journal:  Br J Gen Pract       Date:  1997-05       Impact factor: 5.386

5.  The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years.

Authors:  K L Nichol; M Goodman
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

Review 6.  Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Authors:  Roger E Thomas; Diane L Lorenzetti
Journal:  Cochrane Database Syst Rev       Date:  2014-07-07

Review 7.  Influenza vaccines in low and middle income countries: a systematic review of economic evaluations.

Authors:  Jördis J Ott; Janna Klein Breteler; John S Tam; Raymond C W Hutubessy; Mark Jit; Michiel R de Boer
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

Review 8.  Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Authors:  Roger E Thomas; Diane L Lorenzetti
Journal:  Cochrane Database Syst Rev       Date:  2018-05-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.